Approval · Notice of Compliance 28229 · 2022
CELESTONE SOLUSPAN: Notice of Compliance 28229
Issued May 20, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28229
- Date
- May 20, 2022
- Company
- Organon Canada Inc.Kirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CELESTONE SOLUSPAN | Not yet assigned | — |
Medicinal ingredients
- BETAMETHASONE SODIUM PHOSPHATE 3 MG per ML
- BETAMETHASONE ACETATE 3 MG per ML